Huabo Biopharm (shanghai) Co., Ltd.

Jaka Robotics Co., Ltd.

Xiangyang Zhu

Mingqing Cai

Ling Yu

Haijia Yu

Lei Zhang

Shi Chen

Mingyang Li

Jiapeng Wang

Huifeng Jia

Fengxue Zhang

Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1.

Binder against programmed death-ligand and application thereof

The present invention provides an anti-PD-L1/VEGF bispecific antibody and a use thereof. Specifically, the present invention provides a bifunctional antibody, comprising: (a) anti-PD-L1 antibody or element; and (b) an anti-VEGF antibody or element linked to the anti-PD-L1 antibody or element. The bifunctional antibody of the present invention can simultaneously bind to VEGF and PD-L1, thereby exerting a therapeutic effect on VEGF and PD-L1-positive tumor cells (especially malignant tumor cells).

Anti-PD-L1/VEGF bifunctional antibody and use thereof

A robot control method, a device, and a remote control system. A mobile terminal establishes connection to a robot by scanning a two-dimensional code and by a local area network. A remote monitoring and control center connects to the mobile terminal by a wide area network, and when the mobile terminal and the remote monitoring and control center send information to each other, the mobile terminal breaks off connection with the robot, thereby ensuring information transmission security. Operation instruction information from a user on an operation interface is acquired, the operation instruction information comprising a control parameter and an action execution parameter, and based on the set control parameter and the set action execution parameter, first control instruction information is generated, and sent to the robot by a wireless communications network, in order to cause the robot to execute a corresponding action based on the first control instruction information.

Robot control method, device, and remote control system

The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.

Antibody targeting interleukin 17A and preparation method and application thereof

Growing community of inventors

Shanghai, China

Xiangyang Zhu